IP Library Granted Patent US 7,776,913
Granted Patent B2
US 7,776,913 · App. 12/076,256 · Granted Aug 17, 2010

Carnitines for treating or preventing disorders caused by andropause

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,776,913
App. No.
12/076,256
Granted
Aug 17, 2010
Kind
B2
Abstract

L-carnitine, propionyl L-carnitine and/or acetyl L-carnitine are used to prevent or treat disorders of male andropause caused by ageing or by chemical or surgical castration.

Claims (118)

1. A method of treating the symptoms of disorders caused by andropause wherein said symptoms are selected from the group consisting of: reduced libido or sexual drive and reduced quality of erections, including nocturnal erections, depression of mood and fatigue comprising

administering to a male subject in need of same L-carnitine, acetyl L-carnitine and propionyl L-carnitine or a pharmaceutically acceptable salt thereof, wherein the administration is according to the following schedule.:

SCHEDULE OF TREATMENT

L-

L-

Acetyl

Propionyl L-

Propionyl L-

carnitine

carnitine

L-carnitine

carnitine

carnitine

DAY

4 g/day

2 g/day

2 g/day

1 g/day

2 g/day

1

+

2

+

3

+

4

+

5

+

6

+

7

+

8

+

+

9

+

+

10

+

+

11

+

+

12

+

+

13

+

+

14

+

+

15

+

+

16

+

+

17

+

+

18

+

+

19

+

+

20

+

+

21

+

+

22

+

+

23

+

+

24

+

+

25

+

+

26

+

+

27

+

+

28

+

+

29

+

+

30

+

+

31

+

+

1

+

+

2

+

+

3

+

+.

2. The method according to claim 1 , in which the andropause is caused by aging.

3. The method according to claim 1 , in which the andropause is caused by chemical or surgical castration.

4. The method according to claim 1 , in which the pharmaceutically acceptable salt is selected from the group consisting of: chloride, bromide, orotate, acid aspartate, acid citrate, magnesium citrate, acid phosphate, fumarate, and acid fumarate, magnesium fumarate, lactate, maleate and acid maleate, mucate, acid oxalate, pamoate, acid pamoate, acid sulphate, glucose phosphate, tartrate, acid tartrate, magnesium tartrate, 2-amino-ethane sulphonate, magnesium 2-amino-ethane sulphonate, choline tartrate and trichloroacetate.

5. The method according to claim 1 , in which L-carnitine, propionyl L-carnitine and acetyl L-carnitine are in any form suitable for oral or parenteral administration.

Assignments (2)
MERGER Recorded Nov 14, 2017
From: SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A.
To: ALFASIGMA S.P.A.
Reel/Frame 044760/0906 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 28, 2008
From: KOVERECH, ALEARDO; BIAGIOTTI, GIULIO; CAVALLINI, GIORGIO
To: SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A.
Reel/Frame 021332/0217 →